We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: targeted therapy
MedXY News
EnglishTag

targeted therapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersclinical trialsartificial intelligenceHypertensionCardiologyoncologytype 1 diabetespublic healthMortalitydiabetesAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Alectinib Sets a New Benchmark for Survival in ALK-Positive NSCLC: Final Results from the ALEX Trial
newsoverall survivaltargeted therapy

Alectinib Sets a New Benchmark for Survival in ALK-Positive NSCLC: Final Results from the ALEX Trial

By MedXY|Jan 9, 2026

The final analysis of the Phase III ALEX trial confirms alectinib’s superior long-term efficacy over crizotinib, achieving a median overall survival of 81.1 months and significant intracranial benefits, solidifying its role as the fir

High Efficacy of Pemigatinib in Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Insights from the FIGHT-203 Trial
Hematology-OncologyFGFR1 RearrangementPemigatinib

High Efficacy of Pemigatinib in Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Insights from the FIGHT-203 Trial

By MedXY|Dec 31, 2025

The FIGHT-203 phase 2 trial demonstrates that pemigatinib, a selective FGFR inhibitor, induces high rates of complete clinical and cytogenetic responses in patients with FGFR1-rearranged myeloid/lymphoid neoplasms, offering a potent targete

Targeting MET Amplification: Vebreltinib Shows Robust Antitumor Activity in Advanced NSCLC
newsMET amplificationNSCLC

Targeting MET Amplification: Vebreltinib Shows Robust Antitumor Activity in Advanced NSCLC

By MedXY|Dec 23, 2025

The Phase 2 KUNPENG trial demonstrates that vebreltinib, a selective MET inhibitor, achieves a 48.8% objective response rate in patients with MET-amplified advanced non-small-cell lung cancer, regardless of prior treatment history, offering

Hematology-Oncologyclinical trialsmeasurable residual disease

MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment

By MedXY|Dec 19, 2025

The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep

Hematology-OncologyCLLIbrutinib

Fixed-Duration Therapy Challenging the Continuous Paradigm in Chronic Lymphocytic Leukemia: Insights from the CLL17 Trial

By MedXY|Dec 19, 2025

The Phase 3 CLL17 trial demonstrates that fixed-duration venetoclax-based regimens are noninferior to continuous ibrutinib in previously untreated CLL, offering deep molecular responses and comparable progression-free survival while allowin

Quizartinib Added to Standard Chemotherapy Improves Event-Free and Overall Survival in Newly Diagnosed FLT3‑ITD–Negative AML: Findings from the Phase II QUIWI Trial
Hematology-Oncologyacute myeloid leukemiatargeted therapy

Quizartinib Added to Standard Chemotherapy Improves Event-Free and Overall Survival in Newly Diagnosed FLT3‑ITD–Negative AML: Findings from the Phase II QUIWI Trial

By MedXY|Dec 10, 2025

In the randomized, double‑blind phase II QUIWI trial, adding quizartinib to standard induction/consolidation chemotherapy and single‑agent maintenance significantly improved event‑free survival and overall survival for adults 18–70 years wi

Encorafenib Plus Binimetinib in BRAF V600E-Mutant Metastatic NSCLC: Insights from the Phase II PHAROS Study and Updated Survival Outcomes
Clinical UpdatesBRAF V600Eencorafenib

Encorafenib Plus Binimetinib in BRAF V600E-Mutant Metastatic NSCLC: Insights from the Phase II PHAROS Study and Updated Survival Outcomes

By MedXY|Dec 9, 2025

The Phase II PHAROS study demonstrates durable antitumor efficacy and manageable safety of encorafenib plus binimetinib in BRAF V600E-mutant metastatic NSCLC, with updated results showing the longest median overall survival reported for tar

Oral KRAS G12D inhibitor GFH375 produces ORR 40.7% and DCR 96.7% in previously treated KRAS G12D pancreatic ductal adenocarcinoma: Key readouts from ESMO 2025
newsKRAS G12DPancreatic Cancer

Oral KRAS G12D inhibitor GFH375 produces ORR 40.7% and DCR 96.7% in previously treated KRAS G12D pancreatic ductal adenocarcinoma: Key readouts from ESMO 2025

By MedXY|Nov 24, 2025

A global phase I/II study of oral GFH375 in previously treated KRAS G12D mutant PDAC showed a 40.7% ORR, 96.7% DCR, median PFS 5.52 months, and manageable toxicity, supporting ongoing phase III evaluation.

Doublet Chemotherapy Plus EGFR/BRAF Targeting Yields Best Survival in Advanced BRAF‑Mutated Colorectal Cancer: A 4,633‑Patient Network Meta‑Analysis
Gastroenterologycolorectal cancertargeted therapy

Doublet Chemotherapy Plus EGFR/BRAF Targeting Yields Best Survival in Advanced BRAF‑Mutated Colorectal Cancer: A 4,633‑Patient Network Meta‑Analysis

By MedXY|Nov 21, 2025

A BMJ systematic review and network meta‑analysis of 60 studies (4,633 patients) finds doublet chemotherapy combined with anti‑EGFR/BRAF therapy offers the best first‑line overall survival for advanced BRAF‑mutant colorectal cancer; anti‑EG

Trastuzumab Deruxtecan Plus Pertuzumab: A Promising First-Line Therapy for HER2-Positive Metastatic Breast Cancer
newsHER2-positive breast cancermetastatic breast cancer

Trastuzumab Deruxtecan Plus Pertuzumab: A Promising First-Line Therapy for HER2-Positive Metastatic Breast Cancer

By MedXY|Oct 31, 2025

Trastuzumab deruxtecan combined with pertuzumab significantly improves progression-free survival over standard therapy in first-line HER2-positive metastatic breast cancer, offering enhanced response duration with manageable safety.

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope
newsHER2-mutant NSCLConcology

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

By MedXY|Oct 25, 2025

This article reviews recent clinical trial data showing sevabertinib’s efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances
newsamivantamabEGFR-Mutant NSCLC

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances

By MedXY|Oct 25, 2025

This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib
OncologyeGFRNSCLC

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib

By MedXY|Oct 25, 2025

This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.

Innovative Immunotherapy Combines to Transform Treatment of HER2-Expressing Advanced Urothelial Cancer
OncologyHER2immunotherapy

Innovative Immunotherapy Combines to Transform Treatment of HER2-Expressing Advanced Urothelial Cancer

By MedXY|Oct 24, 2025

This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment
Diabetes & EndocrinologyBelzutifanParaganglioma

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

By MedXY|Oct 24, 2025

This article reviews a phase 2 trial of belzutifan, a HIF-2α inhibitor, demonstrating durable antitumor activity and manageable safety in advanced pheochromocytoma and paraganglioma, highlighting its potential as a targeted therapy.

Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan
OB/GYN & Women's HealthimmunotherapySacituzumab Govitecan

Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan

By MedXY|Oct 24, 2025

This review discusses a phase 3 trial demonstrating that sacituzumab govitecan improves progression-free survival in untreated, advanced triple-negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.

Real-World Insights into HER2-Positive Metastatic Breast Cancer Treatments: Comparing T-DXd, T-DM1, and Tucatinib
Internal MedicineHER2-positive breast cancerreal-world evidence

Real-World Insights into HER2-Positive Metastatic Breast Cancer Treatments: Comparing T-DXd, T-DM1, and Tucatinib

By MedXY|Oct 18, 2025

This study uses real-world data to compare the effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib in HER2-positive metastatic breast cancer, confirming their clinical value.

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib
Nephrologyclinical trialimmunotherapy

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib

By MedXY|Oct 16, 2025

This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data
newsbreast cancerprognostication

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data

By MedXY|Oct 15, 2025

This retrospective UK study reveals that integrating whole-genome sequencing with clinical and mortality data enhances prognostication and identifies therapeutic targets in breast cancer, particularly in ER-positive, HER2-negative subtypes.

Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial
Clinical Updatesimmunotherapylenvatinib

Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial

By MedXY|Oct 8, 2025

The PECATI phase 2 trial demonstrates that lenvatinib combined with pembrolizumab offers encouraging antitumour activity and a manageable safety profile in platinum-refractory metastatic B3 thymoma and thymic carcinoma, a population with li

Prev
2 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure